UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1551-1560

2016

Volltextzugriff (PDF)

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-01, Vol.19 (1), p.29-34

2019

Volltextzugriff (PDF)

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

The Lancet (British edition), 2000-05, Vol.355 (9218), p.1875-1881

2000

Volltextzugriff (PDF)

P-423 Salvage Autologous PBSC Transplantation for tMDS and AML Leads to Remission and Long-Term Disease Control

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S279-S279

2024

Volltextzugriff (PDF)

Exercise And The Development Of Transthyretin Amyloid Cardiomyopathy - Is There An Association?

Journal of cardiac failure, 2022-04, Vol.28 (5), p.S27-S27

2022

Volltextzugriff (PDF)

P-156 Cryotherapy Prevents Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S129-S129

2024

Volltextzugriff (PDF)

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen

Experimental hematology, 2022-10, Vol.114, p.54-60

2022

Volltextzugriff (PDF)

P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S98-S98

2023

Volltextzugriff (PDF)

MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S502-S502

2023

Volltextzugriff (PDF)

POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S221-S221

2023

Volltextzugriff (PDF)

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Clinical lymphoma, myeloma and leukemia, 2024-01, Vol.24 (1), p.55-63

2024

Volltextzugriff (PDF)

Identification of a New, Unorthodox Member of the MAGE Gene Family

Genomics (San Diego, Calif.), 1999-07, Vol.59 (2), p.161-167

1999

Volltextzugriff (PDF)

The role of human and viral cytokines in the pathogenesis of multiple myeloma

Seminars in cancer biology, 2000-10, Vol.10 (5), p.383-391

2000

Volltextzugriff (PDF)

A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e249-e250

2019

Volltextzugriff (PDF)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e249-e249

2019

Volltextzugriff (PDF)

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17, p.S335-S336

2017

Volltextzugriff (PDF)

Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution

Developmental and comparative immunology, 2000-12, Vol.24 (8), p.719-731

2000

Volltextzugriff (PDF)

Pre-Emptive Donor-Derived Innate Immune Cell Add-Back after Haploidentical Hematopoietic Stem Cell Transplantation to Reduce High Rate of Infection, Gvhd, and Non-Relapse Mortality

Biology of blood and marrow transplantation, 2020-03, Vol.26 (3), p.S273-S273

2020

Volltextzugriff (PDF)

Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells

Cellular immunology, 1995-05, Vol.162 (2), p.248-255

1995

Volltextzugriff (PDF)

EFFECTS OF ZOLEDRONIC ACID DOSE AND INFUSION RATE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND RENAL FUNCTION IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER

The Journal of urology, 2008, Vol.179 (4), p.181-181

2008

Volltextzugriff (PDF)

AUTOLOGOUS TRANSPLANTATION

Hematology/oncology clinics of North America, 1999-10, Vol.13 (5), p.969-986

1999

Volltextzugriff (PDF)

The role of nuclear factor-[kappa ]B in the biology and treatment of multiple myeloma

Seminars in oncology, 2001-12, Vol.28 (6), p.626-633, Article asonc0280626

2001

Volltextzugriff (PDF)

The role of nuclear factor-κb in the biology and treatment of multiple myeloma

Seminars in oncology, 2001, Vol.28 (6), p.626-633

2001

Volltextzugriff (PDF)

The role of nuclear factor-κB in the biology and treatment of multiple myeloma: New approaches to the treatment of multiple myeloma

Seminars in oncology, 2001, Vol.28 (6), p.626-633

2001

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

P-423 Salvage Autologous PBSC Transplantation for tMDS and AML Leads to Remission and Long-Term Disease Control

Exercise And The Development Of Transthyretin Amyloid Cardiomyopathy - Is There An Association?

P-156 Cryotherapy Prevents Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen

P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Identification of a New, Unorthodox Member of the MAGE Gene Family

The role of human and viral cytokines in the pathogenesis of multiple myeloma

A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution

Pre-Emptive Donor-Derived Innate Immune Cell Add-Back after Haploidentical Hematopoietic Stem Cell Transplantation to Reduce High Rate of Infection, Gvhd, and Non-Relapse Mortality

Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells

EFFECTS OF ZOLEDRONIC ACID DOSE AND INFUSION RATE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND RENAL FUNCTION IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER

AUTOLOGOUS TRANSPLANTATION

The role of nuclear factor-[kappa ]B in the biology and treatment of multiple myeloma

The role of nuclear factor-κb in the biology and treatment of multiple myeloma

The role of nuclear factor-κB in the biology and treatment of multiple myeloma: New approaches to the treatment of multiple myeloma

Aktive Filter

Suchergebnisse filtern